Speakers: Shifeng Pan PhD (Executive Director, Discovery Chemistry; Novartis Institutes for Biomedical Research)
Organizers: Dewakar Sangaraju, Cyrus Khojasteh and Dennis Hu (all of Genentech)
Date: 2021-01-14
Time: 12:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-04-12  (it will close sooner if the seating cap is reached)

About the Topic

After 18 years of research and development, MAYZENT (siponimod) was approved by FDA in 2019 for the treatment of secondary progressive multiple sclerosis with active disease. Siponimod is the first therapy demonstrating statistically significant delay of disability progression in this patient population. In this presentation, we will share the R&D journey of MAYZENT.

This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry).

Shifeng Pan, PhD
Executive Director, Discovery Chemistry
Novartis Institutes for Biomedical Research, GNF

Dr. Shifeng Pan currently serves as Executive Director of Discovery Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF), where he is responsible for discovery chemistry efforts at the Institute. He leads a team of approximately 70 chemists who are working to discover small molecule therapeutics and drug conjugates across multiple disease areas. In addition, he has responsibility for the Drug Metabolism and Pharmacokinetics (DMPK), Analytical Chemistry, and Compound Management groups at GNF. Since joining GNF in 1999 as one of the founding chemists, he has directly contributed to discover over ten clinical candidates including three approved drugs, Odomzo® (sonidegib) and BRAFTOVI® (encorafenib), and MAYZENT® (siponimod). In 2010, he received the prestigious VIVA award as a Novartis Leading Scientist. Dr. Pan received his Ph.D. in organic chemistry from New York University and B.S. in chemistry from Fudan University in Shanghai, China.